Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04636814 · ClinicalTrials.gov registry record · Phase 3
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
A Phase 3 study, sponsored by Chiesi Farmaceutici S.p.A..
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,973
- Enrollment target
NCT04636814 is a Phase 3 study that was terminated before completion, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 3,973 participants.
The verdict
NCT04636814, a Phase 3 study, was terminated before completion, sponsored by Chiesi Farmaceutici S.p.A..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,973 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Interventions
- DRUG Placebo
- DRUG Roflumilast
- DRUG CHF6001 1600µg
- DRUG CHF6001 3200µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,973 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2025-12-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04636814
The ClinicalTrials.gov registry entry for NCT04636814 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 3,973 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04636814 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04636814 about?
NCT04636814 is a clinical study titled "A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)". The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
What is the current status of trial NCT04636814?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,973 participants. The study started on 2021-07-12. Estimated completion is 2025-12-23.
What interventions are being tested in trial NCT04636814?
The interventions under investigation include: Placebo (DRUG), Roflumilast (DRUG), CHF6001 1600µg (DRUG), CHF6001 3200µg (DRUG).
Who is sponsoring clinical trial NCT04636814?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.